… Alzheimer's disease depicted as a continuum: challenges for therapy. Pathophysiological …
Given that AD largely associates with memory loss, it is not surprising that the vast majority of …

… Alzheimer’s disease (AD) is a neurodegenerative disorder of the central nervous system
associated with progressive cognitive and memory loss. Molecular hallmarks of the disease are …

… of presenilin (PS) function in the forebrain leads to memory loss, synaptic … in Alzheimer's
disease. These results also suggest that, at least in the familial forms of Alzheimer's disease …

… the health systems unless a cure for AD is found—or at least any therapy that postpones
the … the increasing loss of synapses and neurons first described by Alois Alzheimer in 1907. …

… Alzheimer's disease (AD) is the most common cause of dementia, which is defined as a
significant, persistent, and progressive memory loss combined with cognitive impairment and …

… A change in the way glutamate transmits signals within the brain is related to memory loss
that accompanies the AD. Furthermore, hyper stimulation of NDMA receptors can result in …

… Furthermore, JNK3 upregulation was detected in the CSF and was associated with
memory loss. Thus, JNK3 inhibition remains a promising target for future therapies [81]. …

… Different PPAR-γ agonists attenuated the detrimental effects of Aβ 40 on LTP [120], and
rosiglitazone improved learning and memory deficits in the Tg2576 mouse model [121]. Taken …

… Alzheimer’s disease (AD) is a progressive neurodegenerative disease in the elderly with
dementia, memory loss, and severe cognitive impairment that imposes high medical costs on …

… Therapies to alleviate the loss of memory associated with the dysfunctional … in Alzheimer’s
disease vary greatly. There are two principal trends in potential Alzheimer’s disease therapy …